

| Regimens | Total patients | Metastatic patients | Non-Metastatic patients |
|--|-----------------------|----------------------------|--------------------------------|
| Capecitabine | <5 | <5 | <5 |
| CAPIRI | 0 | 0 | 0 |
| CAPOX | 9 | <5 | 6 |
| Cetuximab with FOLFIRI | 0 | 0 | 0 |
| Cetuximab with FOLFOX | 0 | 0 | 0 |
| Cetuximab as a single agent | 0 | 0 | 0 |
| Cetuximab with Encorafenib | 0 | 0 | 0 |
| Irinotecan as a single agent | 0 | 0 | 0 |
| FOLFIRI | <5 | <5 | 0 |
| FOLFOX | <5 | <5 | 0 |
| Fluorouracil (5FU) as a single agent | 0 | 0 | 0 |
| Oxaliplatin as a single agent | 0 | 0 | 0 |
| Nivolumab with Ipilimumab | 0 | 0 | 0 |
| Panitumumab with FOLFIRI | 0 | 0 | 0 |
| Panitumumab with FOLFOX | <5 | <5 | 0 |
| Panitumumab as a single agent | 0 | 0 | 0 |
| Pembrolizumab | <5 | <5 | <5 |
| Any other systemic anti-cancer therapy | <5 | <5 | 0 |
| Palliative care only | 8 | 7 | <5 |